Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Cannatonic** is a balanced hybrid cannabis strain (50% sativa/50% indica) developed by Resin Seeds through crossing MK Ultra and G13 Haze (or variants like Reina Madre and NYC Diesel in some reports), renowned for its high CBD content (typically 12-17%) and low THC (6-8%), yielding a near 1:1 ratio that provides therapeutic relief without significant psychoactive effects. It features an earthy, woody aroma with citrus and pine notes, driven by dominant terpenes including myrcene (anti-inflammatory, sedative), limonene (mood-enhancing), beta-caryophyllene (analgesic, anxiolytic via CB2 receptor binding), linalool (anti-anxiety, anti-inflammatory), and pinene (anti-inflammatory). Primarily used medically for chronic pain, muscle spasms, migraines, inflammation (e.g., arthritis), anxiety, stress, depression, PTSD, neuropathic pain, epilepsy, and conditions like multiple sclerosis, Crohn's disease, and cancer symptoms, it induces mellow relaxation, clear-headed focus, and uplifting effects suitable for daytime use.[1][2][3][7][9]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cannatonic.